AstraZeneca’s tremelimumab drug fails to meet survival endpoint in mesothelioma trial
The trial of 10 mg/kg tremelimumab monotherapy in second or third-line treatment of unresectable malignant mesothelioma failed to hit its primary target. AstraZeneca senior vice president, head of
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.